MINNEAPOLIS, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the publication of new data demonstrating the potential value of the Aquadex SmartFlow® system’s aquapheresis therapy when treating patients with fluid overload as a result of end-stage liver disease.

明尼阿波利斯，2024年2月6日（环球通讯社）--专注于改变体液超负荷患者生活的医疗技术公司Nuwellis，Inc.（Nasdaq:NUWE）今天宣布发布新数据，证明Aquadex SmartFlow®系统在治疗因终末期肝病导致的体液超负荷患者时的潜在价值。

The publication, “Utilization of Aquapheresis Among Hospitalized Patients with End-Stage Liver Disease: A Case Series and Literature Review,” is a single-center retrospective case series featured in Clinical Transplantation. “This study presents an exciting new market opportunity for Nuwellis, and we look forward to gathering additional data demonstrating how Aquadex can benefit these patients,” said Nestor Jaramillo, Jr., president and chief executive officer of Nuwellis.

该出版物“终末期肝病住院患者的水分离利用：病例系列和文献综述”是临床移植中的单中心回顾性病例系列。Nuwellis总裁兼首席执行官NestorJaramillo说：“这项研究为Nuwellis提供了一个令人兴奋的新市场机会，我们期待着收集更多数据，证明Aquadex如何使这些患者受益。”。

“Four and a half million adults in the U.S. have been diagnosed with liver disease.1 To date, there has been little to no clinical evidence gathered demonstrating the benefits of aquapheresis for patients with liver disease. This publication lays the foundation for a new clinical application already within our current labeling that requires no additional regulatory clearances from the FDA.” The case series assessed the utilization of aquapheresis therapy with Aquadex in the intensive care unit (ICU) setting at Mount Sinai Hospital between January 2020 and July 2023.

“美国有450万成年人被诊断出患有肝病。1迄今为止，几乎没有临床证据证明水采对肝病患者有益。本出版物为我们目前的标签中已经存在的一种新的临床应用奠定了基础，该标签不需要FDA的额外监管许可。“该病例系列评估了2020年1月至2023年7月期间，西奈山医院重症监护病房（ICU）使用Aquadex进行水分离治疗的情况。

Fourteen severely ill patients with end-stage liver disease were treated with aquapheresis during this period. The most common cause of liver disease was alcohol-related, with nine of the 14 patients presenting with alcohol-associated cirrhosis. Key findings from the case series include: Six patients were able to receive physical therapy following treatmen.

在此期间，对14名终末期肝病重症患者进行了水采治疗。肝病最常见的原因是与酒精有关，14名患者中有9名患有酒精相关性肝硬化。该病例系列的主要发现包括：六名患者在治疗后能够接受物理治疗。